For years, patients with Hidradenitis Suppurativa (HS) faced limited options—often cycling through treatments that didn’t last.
But today, we are seeing real change.
New therapies, smarter research, and better care strategies are offering renewed hope for patients and healthcare providers alike.
Here’s a look at the major advancements shaping HS treatment so far in 2025.
Sonelokimab Expands its Reach in HS Research
January 8, 2025
MoonLake announced three new clinical trials for Sonelokimab, a nanobody therapy already in Phase III trials for adult HS.
The new studies will include adolescents and other skin conditions, signaling confidence in early results.
With a different mechanism than Humira or Bimzelx, Sonelokimab may offer a new option for patients who haven’t responded to existing treatments.
CRP Levels Identified as a Predictor for Humira Response
January 12, 2025
Researchers at Beth Israel Deaconess Medical Center found that high C-reactive protein (CRP) levels are linked to lower success rates with Humira.
This discovery could help clinicians better personalize treatment plans, sparing patients from ineffective therapies and helping them find the right option sooner.
New Data Highlights the Impact of Draining Tunnels
February 4, 2025
An international study of 580 HS patients confirmed that draining tunnels significantly worsen quality of life, increasing pain, scarring, and work impairment.
These findings emphasize why research is increasingly focused on preventing tunnel formation and addressing more severe forms of the disease.
Updated Guidelines Aim to Improve HS Management
March 4, 2025
New North American clinical guidelines were published with 118 expert recommendations for managing HS across different patient populations.
The update reflects the latest research and patient needs, giving clinicians more tools to deliver effective, individualized care.
Biologics Compared for Early and Long-Term HS Control
March 10, 2025
A new meta-analysis evaluated biologics for HS based on achieving HiSCR50 (50% reduction in abscesses and nodules) within 12–16 weeks:
Humira (adalimumab) showed the strongest early response and best safety profile.
Bimekizumab (Bimzelx) outperformed secukinumab slightly, but early differences were modest.
Importantly, recent 2-year data shows Bimekizumab achieves HiSCR90 (90% improvement) in over 50% of participants, compared to significantly lower rates with Humira.
This suggests Bimekizumab may offer better long-term outcomes for patients seeking deeper, sustained results.
Povorcitinib: A New Oral Option for HS Patients
March 17, 2025
Incyte’s povorcitinib, an oral JAK1 inhibitor, achieved 40–42% response rates in Phase III trials.
While not as strong as some leading biologics, povorcitinib could become a valuable option for patients who don’t respond to first-line therapies, offering another path to relief.
Looking Ahead
Research in HS is moving faster than ever before.
New treatments, smarter diagnostics, and evolving care strategies are creating more options—and more hope—for patients everywhere.
The future of HS care is changing. We can’t wait.
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal guidance.
